How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome. The diagnosis of the condition requires ruling out potential ...

Studies have also evaluated the use of carvedilol in patients with HFPEF. [31] A small, single-center, unblinded study that included 40 Japanese patients with ejection fraction ≥45% found that ...

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

The press release highlights the poor prognosis for patients with heart failure with preserved ejection fraction (HFpEF), indicating a significant unmet medical need which could suggest challenges ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...